Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07020819 · ClinicalTrials.gov registry record · Phase 3
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
A Phase 3 study of Guillain-Barre Syndrome, sponsored by Annexon.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 9
- Study locations
NCT07020819: Recruiting Phase 3 study of Guillain-Barre Syndrome, sponsored by Annexon.
NCT07020819 is a Phase 3 study of Guillain-Barre Syndrome that is actively recruiting participants, run by Annexon. The registered enrollment target is 30 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07020819, a Phase 3 study of Guillain-Barre Syndrome, is actively recruiting participants, sponsored by Annexon.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 9
- Study locations
Study Summary
The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
Conditions Studied
Interventions
- DRUG Tanruprubart
Study Locations (9)
California
- Children's Hospital of Orange County - Orange
- University of California Irvine - Orange
Arizona
- HonorHealth Bob Bové Neuroscience Institute - Scottsdale
Colorado
- University of Colorado Hospital - Aurora
Louisiana
- Ochsner LSU Health - Shreveport
Massachusetts
- University Massachusetts Chan Medical School - Worcester
Michigan
- Henry Ford Health - Detroit
Minnesota
- Mayo Rochester - Rochester
Aarhus N
- Aarhus University Hospital - Aarhus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-12 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 3 |
What NCT07020819 shows while recruiting
NCT07020819 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Guillain-Barre Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Tanruprubart is the first listed.
NCT07020819 lists 9 locations in 8 states (California, Arizona, Colorado).
Frequently Asked Questions
What is clinical trial NCT07020819 about?
NCT07020819 is a clinical study titled "An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)". The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
What is the current status of trial NCT07020819?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2025-09-12. Estimated completion is 2028-06-30.
What conditions does trial NCT07020819 study?
This clinical trial studies the following conditions: Guillain-Barre Syndrome.
What interventions are being tested in trial NCT07020819?
The interventions under investigation include: Tanruprubart (DRUG).
Who is sponsoring clinical trial NCT07020819?
This trial is sponsored by Annexon, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07020819 being conducted?
This trial has 9 study locations across Arizona, California, Colorado, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Guillain-Barre Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07020819's enrollment target sits among peer trials
30 1918th of 2000 higher than 68 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI